Three Stock Lunch: Novo Nordisk, Constellation Brands and Citigroup
James Demmert, Main Street Research CIO, joins 'Power Lunch' to discuss Demmert's investing take on three stocks: Novo Nordisk, Constellation Brands and Citigroup.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Hardman Johnston Global Equity Sold Novo Nordisk (NVO) due to Weak Script Trends
Hardman Johnston Global Advisors, an investment management company, released its 'Hardman Johnston Global Equity Strategy' first quarter 2025 investor letter. A copy of the letter can be downloaded here. The strategy returned 0.43%, net of fees, in the quarter compared to -1.32% for the MSCI AC World Net Index. The Portfolio experienced a solid quarter relative to the market, despite a volatile environment. Industrials and Consumer Discretionary were the top sector contributors, while Information Technology and Energy detracted. Europe was the top contributor from a regional standpoint, while emerging markets detracted. In addition, please check the fund's top five holdings to know its best picks in 2025. In its first-quarter 2025 investor letter, Hardman Johnston Global Equity Strategy highlighted stocks such as Novo Nordisk A/S (NYSE:NVO). Novo Nordisk A/S (NYSE:NVO) engages in the research and development, manufacture, and distribution of pharmaceutical products. The one-month return of Novo Nordisk A/S (NYSE:NVO) was -5.93%, and its shares lost 52.89% of their value over the last 52 weeks. On June 27, 2025, Novo Nordisk A/S (NYSE:NVO) stock closed at $68.51 per share, with a market capitalization of $304.598 billion. Hardman Johnston Global Equity Strategy stated the following regarding Novo Nordisk A/S (NYSE:NVO) in its Q1 2025 investor letter: "Novo Nordisk A/S (NYSE:NVO) was liquidated due to weak script trends while supply ramps up for Wegovy, Novo's semaglutide for diabetes and obesity. Additionally, with the GLP-1 market under pressure, we consolidated our position into Eli Lilly, which has a better near-term outlook as they await trial data for their oral GLP-1." An elderly couple receiving insulin from a pharmacist, representing healthcare company's successful pharmaceutical products. Novo Nordisk A/S (NYSE:NVO) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 60 hedge fund portfolios held Novo Nordisk A/S (NYSE:NVO) at the end of the first quarter, which was 64 in the previous quarter. While we acknowledge the potential of Novo Nordisk A/S (NYSE:NVO) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains. In another article, we covered Novo Nordisk A/S (NYSE:NVO) and shared the list of stocks that will make you rich in 10 years. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 hours ago
- Yahoo
Earnings To Watch: Constellation Brands (STZ) Reports Q2 Results Tomorrow
Beer, wine, and spirits company Constellation Brands (NYSE:STZ) will be reporting results this Tuesday after the bell. Here's what to expect. Constellation Brands beat analysts' revenue expectations by 1.9% last quarter, reporting revenues of $2.16 billion, up 1.2% year on year. It was a mixed quarter for the company, with an impressive beat of analysts' gross margin estimates but full-year EPS guidance missing analysts' expectations. Is Constellation Brands a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Constellation Brands's revenue to decline 4.1% year on year to $2.55 billion, a reversal from the 5.8% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $3.29 per share. Heading into earnings, analysts covering the company have grown increasingly bearish with revenue estimates seeing 8 downward revisions over the last 30 days (we track 15 analysts). Constellation Brands has missed Wall Street's revenue estimates four times over the last two years. Looking at Constellation Brands's peers in the consumer staples segment, some have already reported their Q2 results, giving us a hint as to what we can expect. McCormick posted flat year-on-year revenue, meeting analysts' expectations, and General Mills reported a revenue decline of 3.3%, falling short of estimates by 0.5%. McCormick traded up 3.6% following the results while General Mills was down 5.6%. Read our full analysis of McCormick's results here and General Mills's results here. Investors in the consumer staples segment have had fairly steady hands going into earnings, with share prices down 1.1% on average over the last month. Constellation Brands is down 7.3% during the same time and is heading into earnings with an average analyst price target of $210.29 (compared to the current share price of $161.40). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 hours ago
- Yahoo
Earnings To Watch: Constellation Brands (STZ) Reports Q2 Results Tomorrow
Beer, wine, and spirits company Constellation Brands (NYSE:STZ) will be reporting results this Tuesday after the bell. Here's what to expect. Constellation Brands beat analysts' revenue expectations by 1.9% last quarter, reporting revenues of $2.16 billion, up 1.2% year on year. It was a mixed quarter for the company, with an impressive beat of analysts' gross margin estimates but full-year EPS guidance missing analysts' expectations. Is Constellation Brands a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Constellation Brands's revenue to decline 4.1% year on year to $2.55 billion, a reversal from the 5.8% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $3.29 per share. Heading into earnings, analysts covering the company have grown increasingly bearish with revenue estimates seeing 8 downward revisions over the last 30 days (we track 15 analysts). Constellation Brands has missed Wall Street's revenue estimates four times over the last two years. Looking at Constellation Brands's peers in the consumer staples segment, some have already reported their Q2 results, giving us a hint as to what we can expect. McCormick posted flat year-on-year revenue, meeting analysts' expectations, and General Mills reported a revenue decline of 3.3%, falling short of estimates by 0.5%. McCormick traded up 3.6% following the results while General Mills was down 5.6%. Read our full analysis of McCormick's results here and General Mills's results here. Investors in the consumer staples segment have had fairly steady hands going into earnings, with share prices down 1.1% on average over the last month. Constellation Brands is down 7.3% during the same time and is heading into earnings with an average analyst price target of $210.29 (compared to the current share price of $161.40). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
